Tobias Kind joins Enveda Biosciences as research fellow

Enveda Biosciences today announced that Tobias Kind, Ph.D. will join the company’s data science team as Research Fellow.

Dr Kind will play a key role in driving data science innovation for Enveda’s drug discovery platform.

Dr Kind brings more than 25 years of experience to Enveda through his work in the use of mass spectrometry (MS) for the structural elucidation of small molecules through machine learning, quantum chemistry and other technologies.

He also is widely noted for his articulation of the “Seven Golden Rules,” the use of in silico MS/MS databases and the use of retention time prediction with mass spectrometry, all of which improve biological interpretations of metabolomics data.

Viswa Colluru, Ph.D., Enveda’s CEO, said:

“Dr Kind has extraordinary expertise, particularly with the application of new technologies to the structural elucidation of small molecules, including natural products like those we are targeting.

“We are excited to bring together Dr Kind’s strong record of producing significant innovations and the advances that Enveda’s team already has achieved.

“Dr Kind will play an important role in our efforts to continue to build a discovery platform that is even more powerful, precise and efficient.”

Before joining Enveda, Dr Kind was a team leader and senior researcher at the University of California, Davis.

His research focused on identifying the structures of small molecules with mass spectrometry, predicting in silico mass spectra with quantum chemistry and using machine learning for mass spectral predictions and small molecule identifications.

Dr Kind said:

“It’s a privilege to be a part of Enveda’s team.

“Even before I joined Enveda, I was impressed with the company, its leadership and the calibre of the data science team.

“I have been particularly struck by their innovative advances in spectral inference, an interest of mine, which give Enveda’s process significant advantages.

“I am looking forward to working with my new colleagues to identify new ways to make Enveda’s platform even more powerful.”

Prior to his nearly two decades at UC Davis, Dr Kind was a postdoctoral fellow at Max-Planck-Institute of Molecular Plant Physiology, Golm, Germany.

He was affiliated with the UFZ-Environmental Research Centre Leipzig-Halle’s Department of Chemical Ecotoxicology prior to his time at the Max Planck Society.

He earned his Ph.D. and M.S., both in analytical chemistry, from the University of Leipzig, Germany.